Biocryst Pharmaceuticals buy Royal Bank of Canada
Start price
06.05.25
/
50%
€8.90
Target price
06.05.26
€11.51
Performance (%)
-22.70%
Price
01.08.25
€6.88
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -22.70%. This prediction currently runs until 06.05.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -5.600% | -5.600% |
| iShares Core DAX® | -3.352% | -0.947% |
| iShares Nasdaq 100 | -0.740% | 3.167% |
| iShares Nikkei 225® | -1.885% | -0.531% |
| iShares S&P 500 | -0.952% | 2.583% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $13.00 price target on the stock, up previously from $11.00.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.60
30.06.25
30.06.25
€11.09
30.06.26
30.06.26
-9.52%
01.08.25
01.08.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€5.91
11.04.25
11.04.25
€9.75
11.04.26
11.04.26
16.38%
01.08.25
01.08.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.79
25.02.25
25.02.25
€10.47
25.02.26
25.02.26
-11.68%
01.08.25
01.08.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.61
05.11.24
05.11.24
€9.16
05.11.25
05.11.25
4.05%
01.08.25
01.08.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.95
25.09.23
25.09.23
€9.44
25.09.24
25.09.24
-2.42%
26.09.24
26.09.24